news_6

Takeda Continues Divestiture Strategy with Sale of Select OTC and Non-Core Assets in Europe to Orifarm for Up to Approximately $670M USD

Portfolio includes select OTC and prescription products and two manufacturing facilities Transaction further accelerates Company’s deleveraging plan OSAKA, Japan--(BUSINESS WIRE)--Takeda...

news_6

Positive Results from the Second Phase III SAkuraStar Study for Chugai’s Satralizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) Published in The Lancet Neurology

Satralizumab monotherapy significantly reduced risk of relapse in patients with NMOSD, following a previous positive study where satralizumab was added...